CORTEXA
← Browse
openalexFrontiers in Oncology2026-07-24Cited by 0

The Divide–Survive Matrix: decoupling proliferative drive from intrinsic survival architecture in oncology

Glen Macdonald Heavenor

Tumor behavior is commonly interpreted through proliferative indices and histopathological classification. However, clinical aggression and therapeutic persistence are not fully explained by proliferation alone. Lesions with comparable proliferative activity may demonstrate markedly different trajectories of progression, resistance, or metastatic potential. These discrepancies suggest that proliferative drive and baseline survival programs represent biologically distinct dimensions of tumor behavior. We introduce the Divide–Survive (DvS) Matrix as a structured two-dimensional representation integrating proliferative drive—commonly approximated by Ki-67—and intrinsic survival architecture (ISA), reflecting biological programs that support persistence independent of proliferation. Proliferative positioning may be stratified according to institutional practice or multidisciplinary consensus, including banded aggression categories, ensuring that tumor placement remains clinician-determined rather than prescriptive. ISA is conceptually distinct from therapy-induced adaptive phenomena such as metastatic drug endurance and represents baseline biological positioning at the time of diagnostic biopsy. Matrix positioning is intended as a qualitative-to-semi-quantitative interpretive exercise, guided by multidisciplinary clinical judgement rather than algorithmic assignment. By formally decoupling proliferative activity from survival architecture, the matrix offers a visual interpretive structure through which multidisciplinary teams may assess tumor aggression, clarify discordant behavior, and refine therapeutic reasoning. If prospectively evaluated, this approach may support more biologically aligned prognostic interpretation and therapeutic contextualization across histological subtypes.

View free PDFSource page

Related papers

openalexFrontiers in Oncology2026-07-23

Tumor progression is effectively suppressed by miR-195 through direct targeting of YAP1

Wang Xiao-wei, Jin‐Chao Song, Ming-Ming Tang, Yi-Yu He, Zhigang Cai

Background Yes-associated protein 1 (YAP1) dysregulation is frequently observed in various human cancers. This study aimed to identify microRNAs (miRNAs) capable of suppressing YAP1 expression and to elucidate their functional roles in tumor progression. Methods We screened five…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Editorial: Innovative diagnostic and therapeutic strategies for neuroendocrine tumors: a multidisciplinary approach

Patricia Borges de Souza, Matteo Zurlo, Sara BRAVACCINI, Martina Rosticci, Massimiliano Mazza, Maria Chiara Zatelli

In this context, this Research Topic was conceived to highlight innovative diagnostic and therapeutic strategies to advance precision medicine in NENs. Although the contributions address diverse clinical and translational questions, they converge on a common theme: improving pati…

View free PDFSource page
crossrefFrontiers in Oncology2026-07-09

Plasticizers and prostate cancer: unraveling the link through network toxicology and machine learning

Yiting Jiang, Jiang Shi, Shiwang Yuan, Jun Qiao, Yuan Tian, Peng Chen, et al.

Background Plasticizers, as widespread environmental endocrine disruptors, are increasingly linked to an elevated risk of prostate cancer (PCa). However, the specific molecular mechanisms by which they drive PCa initiation and progression remain incompletely elucidated. Addressin…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells

R K Watanabe, Mami Chosei, Haruna Arai, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika

Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive treatment-associated lineage state emerging with potent androgen receptor (AR) pathway inhibition. Although treatment-emergent NEPC is increasingly recognized, the transcriptional consequences of sustained AR sup…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Phosphorylation of tumour suppressor Amotl2 by IKBKE kinase promotes YAP1 signalling, enhancing glioblastoma growth

Gaochao Guo, Yan Sun, Rujun Hong, Yalin Lu, Xingjie Chen, Liming Zhao, et al.

Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), a member of the serine/threonine kinase family, is an important oncogene in glioblastoma. IKBKE is involved in the progression of multiple tumours in glioblastoma (GBM), including tumour invasion, migration, and…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Spontaneous rupture of a clinically recurrent intracranial dermoid cyst: a case report and narrative review

Hongyuan Liu, Hui Zeng, Bufan Yang, Yuzhu Ji, Zongping Li, Liangxue Zhou

Objective To describe the clinical, pathological, and therapeutic features of spontaneous rupture of a recurrent intracranial dermoid cyst (IDC), and to summarize relevant dermoid-specific literature. Methods We report a 38-year-old woman with a clinical history of resection of a…

View free PDFSource page